---
title: "Haleon plc (HLN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HLN.US.md"
symbol: "HLN.US"
name: "Haleon plc"
industry: "Pharmaceuticals"
datetime: "2026-05-22T01:28:56.881Z"
locales:
  - [en](https://longbridge.com/en/quote/HLN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HLN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HLN.US.md)
---

# Haleon plc (HLN.US)

## Company Overview

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.haleon.com](https://www.haleon.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 45 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.81% |  |
| Net Profit YoY | 21.04% |  |
| P/B Ratio | 1.86 |  |
| Dividend Ratio | 1.97% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 41109541683.52 |  |
| Revenue | 14775653753.83 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 10.23% | B |
| Profit Margin | 15.11% | A |
| Gross Margin | 64.77% | A |
| Revenue YoY | 2.81% | C |
| Net Profit YoY | 21.04% | B |
| Total Assets YoY | 2.05% | C |
| Net Assets YoY | 9.03% | B |
| Cash Flow Margin | 158.01% | B |
| OCF YoY | 2.81% | C |
| Turnover | 0.33 | D |
| Gearing Ratio | 49.48% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Haleon plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.81%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "21.04%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.86",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.97%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "41109541683.52",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "14775653753.83",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "10.23%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "15.11%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "64.77%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.81%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "21.04%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.05%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.03%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "158.01%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "2.81%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.33",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "49.48%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 18.41 | 33/190 | 24.11 | 21.71 | 19.99 |
| PB | 1.86 | 84/190 | 2.21 | 2.01 | 1.91 |
| PS (TTM) | 2.78 | 73/190 | 3.21 | 3.02 | 2.87 |
| Dividend Yield | 1.97% | 21/190 | 1.93% | 1.84% | 1.73% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-30T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 20% |
| Overweight | 2 | 40% |
| Hold | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.32 |
| Highest Target | 13.85 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HLN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HLN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HLN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HLN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**